S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
The Next Big Crisis Is Here (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
The Next Big Crisis Is Here (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
Is This The End of Capitalism? (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
NASDAQ:CEMI

Chembio Diagnostics - CEMI Stock Forecast, Price & News

$0.35
0.00 (0.00%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.33
$0.38
50-Day Range
$0.20
$0.39
52-Week Range
$0.19
$1.24
Volume
511,759 shs
Average Volume
614,859 shs
Market Capitalization
$12.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CEMI stock logo

About Chembio Diagnostics (NASDAQ:CEMI) Stock

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Stock News Headlines

CEMI Chembio Diagnostics, Inc.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Chembio Diagnostics
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Chembio Expands Distribution
Chembio Diagnostics Q1 2022 Earnings Preview
Why Chembio Diagnostics Shares Are Falling
Chembio Diagnostics Q4 2021 Earnings Preview
See More Headlines
Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Company Calendar

Last Earnings
11/03/2022
Today
1/28/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CEMI
Employees
337
Year Founded
N/A

Profitability

Net Income
$-33,900,000.00
Pretax Margin
-60.91%

Debt

Sales & Book Value

Annual Sales
$47.82 million
Book Value
$1.14 per share

Miscellaneous

Free Float
35,497,000
Market Cap
$12.85 million
Optionable
Not Optionable
Beta
1.70

Key Executives

  • Richard L. Eberly
    President, Chief Executive Officer & Director
  • Paul J. Angelico
    Chief Operations Officer & Executive VP
  • Lawrence J. Steenvoorden
    Chief Financial Officer, Secretary & Executive VP
  • Javan Esfandiari
    Executive VP, Chief Science & Technology Officer
  • Paul Lambotte
    Vice President-Research & Development













CEMI Stock - Frequently Asked Questions

Should I buy or sell Chembio Diagnostics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CEMI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CEMI, but not buy additional shares or sell existing shares.
View CEMI analyst ratings
or view top-rated stocks.

How have CEMI shares performed in 2023?

Chembio Diagnostics' stock was trading at $0.2197 at the start of the year. Since then, CEMI shares have increased by 59.4% and is now trading at $0.3501.
View the best growth stocks for 2023 here
.

Are investors shorting Chembio Diagnostics?

Chembio Diagnostics saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 1,580,000 shares, a decrease of 20.2% from the December 31st total of 1,980,000 shares. Based on an average trading volume of 412,400 shares, the days-to-cover ratio is presently 3.8 days.
View Chembio Diagnostics' Short Interest
.

When is Chembio Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our CEMI earnings forecast
.

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics, Inc. (NASDAQ:CEMI) announced its earnings results on Thursday, November, 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $11.20 million for the quarter. Chembio Diagnostics had a negative net margin of 60.93% and a negative trailing twelve-month return on equity of 129.14%.

What other stocks do shareholders of Chembio Diagnostics own?
What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How do I buy shares of Chembio Diagnostics?

Shares of CEMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $0.35.

How much money does Chembio Diagnostics make?

Chembio Diagnostics (NASDAQ:CEMI) has a market capitalization of $12.85 million and generates $47.82 million in revenue each year. The company earns $-33,900,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Chembio Diagnostics have?

The company employs 337 workers across the globe.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The official website for the company is www.chembio.com. The company can be reached via phone at (631) 924-1135, via email at investor@chembio.com, or via fax at 631-924-2065.

This page (NASDAQ:CEMI) was last updated on 1/28/2023 by MarketBeat.com Staff